Trials / Terminated
TerminatedNCT01784861
VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors
A Phase I/II Study of X-82, an Oral Anti-VEGFR Tyrosine Kinase Inhibitor, With Everolimus for Patients With Pancreatic Neuroendocrine Tumors
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 23 (actual)
- Sponsor
- Washington University School of Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is to evaluate the combination of an investigational drug X-82 with everolimus in the treatment of pancreatic neuroendocrine tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | X-82 | |
| DRUG | Everolimus |
Timeline
- Start date
- 2013-05-03
- Primary completion
- 2020-08-19
- Completion
- 2020-08-19
- First posted
- 2013-02-06
- Last updated
- 2021-07-08
- Results posted
- 2021-06-10
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT01784861. Inclusion in this directory is not an endorsement.